Progesterone and FOXO1 signaling: harnessing cellular senescence for the treatment of ovarian cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

1. Female Reproductive Systems: Hormone Dependence and Receptor Expression.Advances in experimental medicine and biology · 2022
   Article
2. ITPKA induces cell senescence, inhibits ovarian cancer tumorigenesis and can be downregulated by miR-203.Aging · 2021
   Article
3. MiR-28-5p promotes human glioblastoma cell growth through inactivation of FOXO1.International journal of clinical and experimental pathology · 2019
   Article
4. A dynamical systems model of progesterone receptor interactions with inflammation in human parturition.BMC systems biology · 2016
   Article

Corrections and comments

• Comment on
  Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.2013

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as